Dapivirine Ring: Phase III Results

Overview of results: Two large clinical trials — The Ring Study and ASPIRE — announced in Feb. 2016 that a monthly vaginal ring containing the antiretroviral drug dapivirine can help prevent HIV in women and is safe for long-term use. Developed by IPM over the past 10 years, the ring reduced infections in the two trials by approximately 30 percent overall. Higher efficacy was seen among women older than 21, who also appeared to use the ring consistently.

Next steps for the ring: This is the first time a microbicide to prevent HIV has confirmed statistically significant efficacy across two Phase III studies. As the first long-acting HIV prevention method, the dapivirine ring could be an important new self-initiated option for women, who bear the greatest burden of the global HIV/AIDS epidemic. IPM, also the regulatory sponsor for the ring, is pursuing approvals from global and national regulatory authorities to license the product in countries where women face the highest risk. Two open-label extension studies, DREAM and HOPE, are now underway to provide the ring to former Ring Study and ASPIRE participants, respectively and to help determine how the ring could fit into women’s lives. DREAM is also enrolling young women ages 18-25 who are using the ring for the first time.

Learn more about the results from the Phase III dapivirine ring studies: